Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer

MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)-- Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced results from a series of preclinical analyses designed to evaluate the binding affinity, lipophilicity, cellular internalization and therapeutic efficacy of ²²⁵Ac-rhPSMA-10.1 in preclinical models for the treatment of prostate cancer, using ¹⁷⁷Lu-rhPSMA-10.1 as a comparator. Results showed that both ²²⁵Ac-rhPSMA-10.1 and ¹⁷⁷Lu-rhPSMA-10.1 demonstrated excellent PSMA binding affinity, high cellular internalization and similar lipophilicity. Therapeutic response and efficacy were evaluated in a preclinical prostate cancer model which showed that ²²⁵Ac-rhPSMA-10.1 significantly suppressed tumor growth relative to control. The data were presented in an oral presentation at the Annual Congress of the European Association of Nuclear Medicine (EANM’23) in Vienna, Austria. ²²⁵Ac-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, and the lead alpha-emitting candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals.

“We are pleased that the first presentation of preclinical results from Blue Earth Therapeutics’ prostate cancer program using rhPSMA-10.1 radiolabeled with ²²⁵Ac is being made to the nuclear medicine community at the EANM’23 Annual Meeting,” said David E. Gauden, D.Phil., Chief Executive Officer of the Company. “Underscoring our commitment to advancing science, we are also honored that the abstract has been recognized as a “Top Rated Oral Presentation” by the Association. ²²⁵Ac-rhPSMA-10.1 is our second pipeline compound, and, like our lead Phase 1/2 compound ¹⁷⁷Lu-rhPSMA-10.1, it is based on innovative radiohybrid PSMA theranostic technology. The radiohybrid platform enables molecules within the class to be modified and deployed for either diagnostic PET imaging or therapeutic applications, and they can also be developed with both beta- and alpha-emitting therapeutic radioisotopes. The pharmacokinetic profile of rhPSMA-10.1 was carefully optimized during development to deliver high radiation doses to prostate cancer lesions while sparing normal tissues as far as possible, and we are building on that work by radiolabeling it with the powerful alpha-emitting radioisotope, ²²⁵Ac.

Dr. Gauden continued, “Results from these preclinical analyses demonstrate a promising therapeutic profile for ²²⁵Ac-rhPSMA‑10.1, while using 1,000-fold lower radioactivity than ¹⁷⁷Lu-rhPSMA-10.1, with similar in vitro characteristics and in vivo therapeutic efficacy observed for both compounds. ²²⁵Ac-rhPSMA-10.1 represents a novel alpha-targeted therapy that we intend to advance into the clinic. IND-enabling studies have been completed and we plan to initiate a Phase 1 clinical study of ²²⁵Ac-rhPSMA-10.1 in the first half of 2024.”

About the study

The findings presented at EANM’23 evaluated ²²⁵Ac-rhPSMA-10.1 and ¹⁷⁷Lu-rhPSMA-10.1 in preclinical models for the treatment of prostate cancer. Binding affinity and cellular internalization assays were conducted in LNCaP cells, using ¹⁷⁷Lu-PSMA-I&T as a reference compound. The lipophilicity of ²²⁵Ac-rhPSMA-10.1 and ¹⁷⁷Lu-rhPSMA-10.1 was determined by the shake-flask method, measuring the distribution coefficient in n-octanol and PBS at pH 7.4 (log D_7.4). Therapeutic response to single-administration of ²²⁵Ac-rhPSMA-10.1 (30 kBq) or ¹⁷⁷Lu-rhPSMA-10.1 (30 MBq) was evaluated in the 22Rv1 preclinical model (n=8 per group). Efficacy was assessed based on relative tumour growth (change in tumour volume from treatment administration day/baseline) and survival of treated groups versus untreated controls ≤49 days post-treatment initiation. Body weights were monitored throughout for toxicity assessment.

Results

Both ^natLa-rhPSMA-10.1 and ^natLu-rhPSMA-10.1 (^natLa and ^natLu being cold surrogates of ²²⁵Ac and ¹⁷⁷Lu) showed excellent PSMA binding affinity (IC₅₀ = 3.6±0.6 nM and 1.6±0.1 nM, respectively). High cellular internalization and similar lipophilicity were observed for both ²²⁵Ac-rhPSMA‑10.1 and ¹⁷⁷Lu-rhPSMA-10.1 (% internalization = 99±14 and 108±5; logD_7.4 = -3.4±0.2 and -3.8±0.1; respectively). ²²⁵Ac-rhPSMA-10.1 treatment significantly reduced tumour growth in vivo versus controls (from day 14 to 31, p<0.05), and prolonged survival (median survival: 27, 43.5, and 42 days for untreated, ²²⁵Ac-rhPSMA-10.1, and ¹⁷⁷Lu-rhPSMA-10.1 groups, respectively). There were no significant differences in tumour growth suppression or survival between the ²²⁵Ac‑rhPSMA-10.1 and ¹⁷⁷Lu-rhPSMA-10.1 groups, and both treatments were well-tolerated.

The results were discussed in an oral presentation, “Preclinical Evaluation of ²²⁵Ac-rhPSMA-10.1, a Novel Radiohybrid PSMA Compound for Targeted Alpha Therapy of Prostate Cancer,” by Caroline Foxton, Ph.D., Blue Earth Group, Oxford, UK, at the Annual Congress of the European Association of Nuclear Medicine on September 10, 2023. Full session details and the abstract are available in the EANM online program here .

About Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA)

rhPSMA compounds are referred to as radiohybrid (“rh”), as each molecule possesses three distinct domains. The first consists of a Prostate-Specific Membrane Antigen-targeted receptor ligand which attaches to and is internalized by prostate cancer cells. It is attached to two labelling moieties which may be radiolabeled with diagnostic isotopes such as ¹⁸F or ⁶⁸Ga for PET imaging, or with therapeutic isotopes such as ¹⁷⁷Lu or ²²⁵Ac for radioligand therapy – enabling the potential for a true theranostic technology. They may play an important role in patient management in the future, and offer the potential for precision medicine for men with prostate cancer. Radiohybrid technology and rhPSMA originated from the Technical University of Munich, Germany. Blue Earth Diagnostics acquired exclusive, worldwide rights to rhPSMA diagnostic imaging technology from Scintomics GmbH in 2018, and therapeutic rights in 2020, and has sublicensed the therapeutic application to its sister company Blue Earth Therapeutics. Blue Earth Therapeutics and Blue Earth Diagnostics work closely on the development of ¹⁷⁷Lu-rhPSMA-10.1. Currently, Blue Earth Therapeutics’ rhPSMA compounds have not received regulatory approval.

About Blue Earth Therapeutics

Blue Earth Therapeutics, one of the Bracco family of companies, is a clinical stage company dedicated to advancing next generation targeted radiotherapeutics to treat patients who have cancer. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start-up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases. Blue Earth Therapeutics has an emerging pipeline, initially focused on prostate cancer, and with plans to expand into additional disease areas in oncology. Blue Earth Therapeutics is an indirect subsidiary of Bracco Imaging S.p.A, and based in Oxford, UK. For more information, please visit: https://www.blueearththerapeutics.com.

About Bracco Imaging

Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies. Visit: www.braccoimaging.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230911149493/en/